Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katherine Zamecki

Ophthalmic Plastic and Reconstructive Surgery Danbury, CT Medical Doctor

NPI 1972764843 CMS profile 89057

69 Sand Pit Rd, Danbury, CT 06810

Open in the dashboard

General payments

$4,624

87 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Zamecki of Danbury, CT is reported in the CMS Open Payments database as having received $4,624 across 87 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Ophthalmic Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $251 17
2024 General $473 26
2023 General $1,875 25
2022 General $1,959 16
2021 General $66 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Zamecki
  • Ophthalmic Plastic and Reconstructive Surgery median
  • Middle half of Ophthalmic Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Katherine Zamecki were reported at $251. Among 325 Ophthalmic Plastic and Reconstructive Surgery profiles paid that year, the median was $298 and the middle half received between $132 and $820.

Show as a table
Year Katherine Zamecki Ophthalmic Plastic and Reconstructive Surgery median Middle half National median
2019 $0 $182 $73–$467 $163
2020 $0 $125 $41–$412 $114
2021 $66 $173 $52–$538 $132
2022 $1,959 $237 $78–$809 $149
2023 $1,875 $291 $103–$776 $160
2024 $473 $304 $108–$822 $164
2025 $251 $298 $132–$820 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Horizon Therapeutics plc $3,458 23 payments
  2. Amgen Inc. $308 24 payments
  3. Sun Pharmaceutical Industries Inc. $223 8 payments
  4. Bausch & Lomb Americas Inc. $121 3 payments
  5. AbbVie, Inc. $106 7 payments
  6. Oyster Point Pharma, Inc. $98 5 payments
  7. Dompe US, Inc. $57 3 payments
  8. Galderma Laboratories, L.P. $49 3 payments
  9. ANI Pharmaceuticals, Inc. $48 3 payments
  10. Merz Pharmaceuticals, LLC $37 1 payment
  11. Other $119 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Honoraria $3,228 2 payments
  2. Food and Beverage $1,397 85 payments
Products named General payments · program years 2021–2025
  1. TEPEZZA Tepezza $3,458 23 payments
  2. TEPEZZA Inflammation/Rare Disease $308 24 payments
  3. Cequa $214 7 payments
  4. MIEBO $106 2 payments
  5. XIIDRA $63 4 payments
  6. BOTOX $60 4 payments
  7. OXERVATE $57 3 payments
  8. TYRVAYA Dry Eye $56 3 payments
  9. PURIFIED CORTROPHIN GEL $48 3 payments
  10. TYRVAYA Dry eyes $41 2 payments
  11. Other $240 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,023

Median for Ophthalmology: 891

Drug cost

$319,252

Median for Ophthalmology: $68,233

Branded share of claims

65.6%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 94 $137,381
Xiidra Lifitegrast Brand 58 $105,185
Cequa Cyclosporine Brand 22 $23,105
Cyclosporine Generic 31 $22,820
Loteprednol Etabonate Generic 119 $14,319
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 139 $5,531
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 261 $2,665
Fluorometholone Generic 34 $2,384
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 15 $1,792
Prednisolone Acetate Generic 57 $1,497

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$243,717

Of which drugs: $74,743

Medicare patients

511

Average age 76

Services billed

17,788

361 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 49%
Ischemic heart disease 23%
Osteoporosis 21%
Diabetes 19%
Chronic kidney disease 18%
Depression 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 27 13,115 $62,014
Injection, incobotulinumtoxin a, 1 unit J0588 Office 19 3,066 $12,562
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 31 229 $164

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Cequa
  • Sun Pharmaceutical Industries Inc. $179
$179 22 —
TEPEZZA
  • Amgen Inc. $133
$133 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $48
$48 — —
BOTOX
  • AbbVie, Inc. $33
$33 — 13,115
TYRVAYA
  • Oyster Point Pharma, Inc. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

87 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmic Plastic and Reconstructive Surgery in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record